

an international reproductive health journal

Contraception

Volume 95, Number 4, April 2017

Publication information: *Contraception* (ISSN 0010-7824) is published monthly by Elsevier Inc., 230 Park Avenue, New York, NY 10169. Periodicals postage paid at New York, NY, and additional mailing offices.
USA POSTMASTER: Send address changes to *Contraception*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

Annual subscription rates: United States and possessions: individual, \$503; institution, \$1,782. All other countries: individual, \$585; institution, \$1,875.

Orders, claims, and journal inquiries: Please contact the Elsevier Customer Service Department nearest you: **St. Louis:** Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (800) 6542452 [toll free within the USA]; (+1) (314) 4478871 [outside the USA]; fax: (+1) (314) 4478029; e-mail: JournalsCustomerService-usa@elsevier.com. **Oxford:** Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: JournalsCustomerServiceEMEA@elsevier.com. **Tokyo:** Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com. **The Philippines:** Elsevier Customer Service Department, 2nd Floor, Building H, UP-Ayalaland Technohub, Commonwealth Avenue, Diliman, Quezon City, Philippines 1101; phone: (+ 65) 6349 0222; Fax: (+ 63) 2 352 1394; email: JournalsCustomerServiceAPAC@elsevier.com

Advertising information: Advertising orders and inquiries can be sent to: USA, Canada and South America: Le-Andrea Sylvester, Elsevier Inc., 230 Park Avenue, New York, NY 10169. Tel: (212) 633-3649, e-mail: le.sylvester@elsevier.com.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, New York, NY 10169. E-mail: reprints@elsevier.com.

Author information: For full and complete Author Information, please go to: <http://www.contraceptionjournal.org/authorinfo>.

Author inquiries: You can track your submitted article at <http://www.elsevier.com/track-submission>. You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

Funding body agreements and policies: Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.
© 2017 by Elsevier Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Inc., and the following terms and conditions apply to their use:


Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK)/(+1) 215 239 3804 (USA).

Derivative Works: Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic Storage or Usage: Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Notice: No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

 This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

Commentaries

- 323** Removing Barriers to Contraception Through Use of Criteria to Assess Pregnancy Risk
Naomi K. Tepper, Kathryn M. Curtis, Tara C. Jatlaoui, Maura K. Whiteman

- 326** Proposed Clinical Guidance for Excluding Pregnancy Prior to Contraceptive Initiation
John Stanback, Irina Yacobson, Lucy Harber

- 331** Does Using the “Pregnancy Checklist” Delay Safe Initiation of Contraception?
Chelsea Morrone, Molly Findley, Carolyn Westhoff

- 335** Immediate Postpartum Long-acting Reversible Contraception: the Time Is Now
Michelle Moniz, Tammy Chang, Michele Heisler, Vanessa K. Dalton

Reviews

- 339** Pharmacy Provision of Sexual and Reproductive Health Commodities to Young People: A Systematic Literature Review and Synthesis of the Evidence
Lianne Gonsalves, Michelle J. Hindin

Original Research

- 364** Risk of Luteal Phase Pregnancy With Any-cycle-day Initiation of Subdermal Contraceptive Implants
Molly Richards, Stephanie B. Teal, Jeanelle Sheeder

- 371** A Single-arm Phase III Study Exploring the Efficacy and Safety of LNG-IUS 8, A Low-dose Levonorgestrel Intrauterine Contraceptive System (total Content 13.5 Mg), in An Asia-Pacific Population
Guangsheng Fan, Sukho Kang, Mulan Ren, Edith Weisberg, Eeva Lukkari-Lax, Katrin Roth, SoYoung Shin

- 378** Use of the Levonorgestrel 52-mg Intrauterine System in Adolescent and Young Adult Solid Organ Transplant Recipients: A Case Series
P.S. Huguelet, C. Sheehan, R.F. Spitzer, S. Scott

- 382** Changes in Body Composition in Women Using Long-acting Reversible Contraception
Priscilla de Nazaré Silva dos Santos, Tessa Madden, Karen Omvig, Jeffrey F. Peipert

(Contents continued)

- 390** Pooled Analysis of Two Randomized, Open-label Studies Comparing the Effects of Nomegestrol Acetate/17 β -estradiol and Drospirenone/ethinyl Estradiol on Bleeding Patterns in Healthy Women
Diana Mansour, Carolyn Westhoff, Uma Kher, Tjeerd Korver
- 398** Estimating Systemic Exposure to Levonorgestrel From An Oral Contraceptive
Cale N. Basaraba, Carolyn L. Westhoff, Malcolm C. Pike, Renu Nandakumar, Serge Cremers
- 405** Effects of Combined Oral Contraceptives, Depot Medroxyprogesterone Acetate and the Levonorgestrel-releasing Intrauterine System on the Vaginal Microbiome
J.Paul Brooks, David J. Edwards, Diana L. Blithe, Jennifer M. Fettweis, Myrna G. Serrano, Nihar U. Sheth, Jerome F. Strauss III, Gregory A. Buck, Kimberly K. Jefferson
- 414** "I Don't Know What I Would Have Done." Women's Experiences Acquiring Ulipristal Acetate Emergency Contraception Online From 2011 to 2015
Nicole K. Smith, Kelly Cleland, Brandon Wagner, James Trussell
- 419** Similarities and Differences in Contraceptive Use Reported By Women and Men in the National Survey of Family Growth
Abigail R.A. Aiken, Yu Wang, Jenny Higgins, James Trussell
- 424** Could Misreporting of Condom Use Explain the Observed Association Between Injectable Hormonal Contraceptives and HIV Acquisition Risk?
Jennifer A. Smith, Renee Heffron, Ailsa R. Butler, Connie Celum, Jared M. Baeten, Timothy B. Hallett
- 431** Contraception and Postpartum Follow-up in Patients With Gestational Diabetes
Emily W. Rosenthal, Sarah Rae Easter, Emma Morton-Eggleston, Caryn Dutton, Chloe Zera
- Correspondence**
- 434** Vaginal Misoprostol Prior to Intrauterine Device Insertion in Women Delivered Only By Elective Cesarean Section: A Randomized Double-blind Clinical Trial
Luis Bahamondes, Ilza Monteiro
- 435** Vaginal Misoprostol Prior to Intrauterine Device Insertion in Women Delivered Only By Elective Cesarean Section — Reply to Letter to the Editor
Ahmed M. Abbas, Mohamed S. Abdellah
- 435** Revisiting Contraceptive Steroid Hormone Pharmacokinetics in Obese Women
Alison B. Edelman, Jeffrey T. Jensen, Ganesh Cherala,